Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis.

Kant, Sam; Geetha, Duvuru

Kant, Sam; Geetha, Duvuru.

Kant S; Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Geetha D; Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: gduvura@jhmi.edu.

Kidney Int ; 100(5): 1124-1127, 2021 11.

Article in English | MEDLINE | ID: covidwho-1428230

Subject(s)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; COVID-19; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy; Antibodies, Antineutrophil Cytoplasmic; COVID-19 Vaccines; Humans; Kinetics; Rituximab/therapeutic use; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Kidney Int Year: 2021 Document Type: Article Affiliation country: J.kint.2021.08.020

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google